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Lymphotoxin‐mediated activation of the lymphotoxin‐β receptor (LTβR; LTBR) has been 
implicated in cancer, but its role in T‐cell acute lymphoblastic leukaemia (T‐ALL) has 
remained elusive. Here we show that the genes encoding lymphotoxin (LT)‐α and LTβ 
(LTA, LTB) are expressed in T‐ALL patient samples, mostly of the TAL/LMO molecular 
subtype, and in the TEL‐JAK2 transgenic mouse model of cortical/mature T‐ALL (Lta, Ltb). 
In these mice, expression of Lta and Ltb is elevated in early stage T‐ALL. Surface 
LTα1β2 protein is expressed in primary mouse T‐ALL cells, but only in the absence of 
microenvironmental LTβR interaction. Indeed, surface LT expression is suppressed in 
leukaemic cells contacting Ltbr‐expressing but not Ltbr‐deficient stromal cells, 
both in vitro and in vivo, thus indicating that dynamic surface LT expression in leukaemic 
cells depends on interaction with its receptor. Supporting the notion that LT signalling plays 
a role in T‐ALL, inactivation of Ltbr results in a significant delay in TEL‐JAK2‐induced 
leukaemia onset. Moreover, young asymptomatic TEL‐JAK2;Ltbr−/− mice present markedly 
less leukaemic thymocytes than age‐matched TEL‐JAK2;Ltbr+/+ mice and interference with 
LTβR function at this early stage delayed T‐ALL development. We conclude that LT 
expression by T‐ALL cells activates LTβR signalling in thymic stromal cells, thus promoting 
leukaemogenesis. 
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T‐cell acute lymphoblastic leukaemia (T‐ALL) is an aggressive malignancy of thymocytes that 
affects mainly children and adolescents, is fatal without therapy, and is characterized by a number 
of cell‐autonomous genetic and molecular alterations (Graux et al, 2006; Van Vlierberghe & 
Ferrando, 2012). Several cell‐extrinsic factors involved in T‐ALL have been 
studied in vitro or in vivo, including growth factors [e.g. interleukin 7 (IL7), IL18 and insulin‐like 
growth factor 1 (IGF1)], chemokines, Notch ligands (DLL4) and adhesion molecules (e.g. ICAM1) 
(Winter et al, 2001; Buonamici et al, 2009; Medyouf et al, 2011; Silva et al, 2011; 
Mirandola et al, 2012; Uzan et al, 2014; Minuzzo et al, 2015). Furthermore, our group has found 
that expression of the NF‐κB transcription factor RELB in non‐haematopoietic stromal cells 
contributes to the development of T‐ALL in a mouse model (dos Santos et al, 2008). RELB is a 
critical NF‐κB transcription factor that is activated following engagement of tumour necrosis factor 
receptor (TNFR) superfamily members, thus hinting that TNFR‐like signalling is implicated in T‐
ALL (dos Santos et al, 2010). 
The lymphotoxin‐beta receptor (LTβR; LTBR) is a member of the TNFR superfamily that is 
activated by either of two ligands, the lymphotoxin (LT) heterotrimer LTα1β2 or LIGHT/TNFSF14 
homotrimer (Ware, 2005; Remouchamps et al, 2011). Expression of LTα1β2 is found at the surface 
of activated T, B and NK cells (Ware et al, 1992; Browning et al, 1993), while LIGHT protein is 
mainly expressed on activated T cells (Mauri et al, 1998). The LTβR receptor is constitutively 
expressed in stromal cells (e.g. fibroblasts, epithelial cells, and endothelial cells) of primary and 
secondary lymphoid organs and in myeloid lineage cells, but not expressed in T or B lymphocytes 
(Force et al, 1995; Murphy et al, 1998). LTβR activates both canonical and noncanonical NF‐κB 
signalling pathways (Dejardin et al, 2002; Ganeff et al, 2011), thus inducing specific transcriptional 
programmes that include the expression of chemokines (e.g. CXCL13, CCL21 and CCL19) and 
adhesion molecules (ICAM1, VCAM1 and MAdCAM1) (Dejardin et al, 2002; Ganeff et al, 2011; 
Bénézech et al, 2012). Knock‐out mouse models inactivating LTβR or downstream signalling 
proteins showed that this pathway is essential for the development of secondary lymphoid organs, 
and for the generation and maintenance of splenic and thymic microarchitecture 
(Remouchamps et al, 2011). In the thymus, the LTα1β2‐LTβR signalling axis is involved not only in 
the development and maintenance of the stromal cell network, but also in thymocyte development, 
which requires reciprocal interactions between thymocytes and stromal cells either by direct cell‐
to‐cell contact or by soluble factor production (Fütterer et al, 1998; Klug et al, 1998; 
Boehm et al, 2003; Ware, 2005). 
Despite early evidence for anti‐tumour properties of the LTβR signalling pathway, several reports 
pinpointed a pro‐oncogenic role for LT signalling in both solid and haematological malignancies 
(Wolf et al, 2010). In some settings, LTβR signalling is expressed in malignant cells and is activated 
by LT‐expressing lymphocytes present in the tumour microenvironment (Haybaeck et al, 2009; 
Ammirante et al, 2010), while in others LTβR is expressed in specific tumour microenvironmental 
cells and is activated by either cancer or other stromal cells expressing LT (Rehm et al, 2011; 
Lau et al, 2014). mRNA and protein expression of LT has long been reported in T‐ALL cell lines 
(Sung et al, 1988; Ware et al, 1992), but the expression in primary T‐ALL as well as its physiological 
relevance in disease development has not yet been addressed. 
Here, we report that T‐ALL patient samples express the LTA and LTB genes, this expression being 
more pronounced in the TAL/LMO molecular subtype. Using the TEL‐JAK2 transgenic mouse 
model of cortical/mature T‐ALL, we document that the LTα1β2 ligand is expressed at the surface of 
TEL‐JAK2 leukaemic cells and that LTβR genetic inactivation leads to a significant delay in T‐ALL 
development. 
MATERIALS AND METHODS 
Mice 
EμSRα‐TEL‐JAK2 transgenic (TJ2‐Tg) mice (Carron et al, 2000) were bred with Ltbr knockout mice 
(Fütterer et al, 1998), provided by Dr. Jorge Caamaño (University of Birmingham, Birmingham, 
UK), all on the C57BL/6 background. Mice were maintained in the specific pathogen‐free 
CBMR/UAlg Animal Facility (Faro, Portugal) and the experimental procedures followed 
recommendations for the care and use of laboratory animals from the European Commission 
(Directive 2010/63/UE) and Portuguese authorities (Decreto‐Lei n°113/2013). TJ2‐Tg and 
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recipient mice were monitored for leukaemia development and killed by CO2 inhalation when 
manifesting signs of disease (i.e. dyspnoea, lethargy, enlarged lymph nodes or enlarged abdomen). 
For LT in vivo inhibition, TJ2‐Tg mice were intraperitoneally injected with 100 μg of muLTβR‐
muIgG fusion protein (provided by Biogen Idec, Cambridge, MA, USA) or control ChromPure mouse 
IgG (Jackson Immunoresearch Laboratories, West Grove, PA, USA) for five consecutive weeks, 
starting at 5 weeks of age. For detection of malignant thymocytes in early stage T‐ALL, TJ2‐Tg mice 
were killed at 8 weeks of age, and the percentage of CD8+CD25+ cells in thymocyte suspensions was 
determined. 
Human T‐ALL and thymocyte samples 
Primary T‐ALL samples were obtained at diagnosis from bone marrow and/or peripheral blood 
with high leukaemia involvement (>85%), and enriched by density centrifugation over Ficoll‐
Paque (GE Healthcare, Little Chalfont, UK). Microarray analyses were performed on samples from 
51 paediatric patients with newly diagnosed T‐ALL accrued from 2000 to 2013 at Centro Infantil 
Boldrini, Campinas, Brazil. Most patients (n = 44) were treated according to the Brazilian GBTLI‐
99 Childhood ALL Treatment protocol (Brandalise et al, 2010). The use of patient samples was 
approved by the FCM/UNICAMP Research Ethics Committee (CAAE: 0014.0.144.146‐08) and 
informed consent was obtained from parents. Thymic samples, obtained from children undergoing 
cardiac surgery, were gently minced in culture medium and subsequently subjected to density 
centrifugation. Informed consent and Institutional Review Board approval were obtained for all 
sample collections in accordance with the Declaration of Helsinki. 
Microarray data sets and data analysis 
Microarray data sets were obtained from the publicly available Gene Expression Omnibus 
database, including gene expression data from the Microarray Innovations In Leukaemia (MILE) 
study (GSE 13159) to evaluate the expression of LTA and LTB in subtypes of leukaemia compared 
to non‐leukaemia and healthy bone marrow samples (Haferlach et al, 2010). To compare the 
expression profile of TJ2‐Tg mouse T‐ALL with that of different stages of mouse thymocyte 
differentiation, we obtained thymocyte gene expression data from the Immunological Genome 
Project (Heng & Painter, 2008) and expression data from TJ2‐Tg leukaemic cells 
(Waibel et al, 2013) (GSE15907 and GSE51243, respectively). All datasets were pre‐processed 
using Robust Multi‐array Average as implemented in the R/Bioconductor environment 
(Gentleman et al, 2004). The log2 signal intensities of the annotated genes were obtained and the 
co‐efficient variation for each gene was computed. We thus obtained the top 1% (n = 163) of genes 
that showed least co‐efficient of variation. Further, we performed hierarchical clustering of 
samples using the complete linkage analysis method implemented in the TM4 software on the 
above mentioned mouse datasets. In addition to the clustering analysis we performed functional 
enrichment analysis of the 163‐gene dataset using Gene Set Enrichment Analysis (GSEA) to identify 
enriched biological processes, molecular functions and pathways (Subramanian et al, 2005). The 
statistical significance of enrichment was estimated and all the functional categories and pathways 
with a false discovery rate of ≤0·05 were considered. 
Gene expression microarray analysis of T‐ALL patient samples 
Total RNA was extracted from 51 paediatric T‐ALL samples preserved in guanidine isothiocyanate 
solution using the Illustra RNAspin Mini RNA Isolation Kit (GE Healthcare). Total RNA from two 
human thymocyte samples was extracted with Trizol (Life Technologies, Carlsbad, CA, USA). RNA 
samples were processed with the WT Expression Kit (Ambion, Austin, TX, USA) and GeneChip WT 
Terminal Labeling and Controls Kit (Affymetrix, Santa Clara, CA, USA), and hybridized on Human 
Gene 1.0 ST Arrays (Affymetrix). Array files are publicly available through the Gene Expression 
Omnibus (GEO) database under the accession numbers GSE50999 and GSE66638. Expression 
values were obtained with the iterPLIER+16 algorithm in the Affymetrix Expression Console, and 
transformed to Z‐score to a log2 scale. Molecular subtypes were classified by hierarchical clustering 
analysis (Pearson correlation and pairwise average‐
linkage; http://genepattern.broadinstitute.org/) according to the expression of genes previously 
associated with each subtype (Homminga et al, 2011). We used the Affymetrix Complex Match 
table to identify those probe sets in the original Human Genome U133 Plus 2.0 Array 
(Homminga et al, 2011) that were most related to probe sets available in the Human Gene 1.0 ST 
Array. Two out of the 51 T‐ALL samples could not be classified and thus were excluded from 
analysis. 
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Human cell lines 
T‐ALL cell lines DND41, PF382, P12 and SUPT1 were provided by Dr. Hind Medyouf and Dr. Andrew 
P. Weng (BC Cancer Agency, Vancouver, Canada). Jurkat and Nalm6 cell lines were available in‐
house (Barata et al, 2006). Leukaemic cell lines were cultured in complete RPMI medium (Lonza, 
Basel, Switzerland) supplemented with 10% heat‐inactivated foetal bovine serum (PAA 
Laboratories, Linz, Austria), 2 mmol/l L‐glutamine, 100 U/ml of penicillin and 100 μg/ml of 
streptomycin (Lonza) and maintained at 37°C under a humidified atmosphere with 5% CO2. Cell 
lines were cultured at 1 × 106 cells/ml and treated for 10 h with either dimethyl sulfoxide (DMSO; 
control), 50 ng/ml phorbol 12‐myristate 13‐acetate (PMA) (Sigma‐Aldrich, St. Louis, MO, USA) 
and/or 10 μmol/l BMS‐345541 (IKKi) (Calbiochem, Billerica, MA, USA) for both mRNA and cell 
surface protein detection. 
Reverse transcription quantitative PCR (RT‐qPCR) 
Total RNA from mouse cells and cell lines was prepared using Trizol reagent (Life Technologies) 
and Direct‐zol RNA miniprep (Zymo Research, Irvine, CA, USA), following the manufacturer′s 
instructions. RNA samples were treated with DNase I (Thermo Fisher Scientific, Waltham, MA, USA) 
to remove remaining genomic DNA. Then, total RNA (1 μg) was reverse‐transcribed using the First 
Strand cDNA Synthesis Kit (Thermo Fisher Scientific) and oligo(dT)18 primers. Quantitative PCR 
reactions, containing 2 μl of 1:20 diluted cDNA in 20 μl, SsoFast EvaGreen Supermix (Bio‐Rad, 
Hercules, CA, USA) and 300 nmol/l of murine or human gene‐specific primers (see Table SI) were 
performed on a C1000 Thermal Cycler coupled to a CFX 96 Real‐time PCR detection system (Bio‐
Rad). PCR results were analysed by Bio‐Rad CFX Manager software, version 3.0, treated using the 
comparative CT method (2−∆∆C(T) method), and the mean fold change in expression of the target 
gene was calculated in relation to reference gene expression (Gapdh for murine samples 
and GAPDH or RNA18S5 rRNA for human samples). For quantification of LTA and LTB expression 
in the molecular subgroups of T‐ALL, total RNA (1 μg) was reverse transcribed using the ImProm 
II Reverse Transcriptase enzyme (Promega, Madison, WI, USA) and random hexamers (25 μmol/l). 
PCR reactions were carried out in 15 μl containing 5 μl of 1:25 diluted cDNA, 7·5 μl Maxima 
Probe/ROX qPCR Master Mix (Thermo Fisher Scientific), 300 nmol/l of each primer and 
200 nmol/l of TaqMan probe (sequences listed in Table SI). Amplification reactions were 
performed in a 7500 Fast Real‐Time PCR System (Life Technologies). Expression values 
of LTA and LTB were calculated by the 2−∆∆C(T) method using ABL1 as endogenous normalizer and 
Jurkat cells as calibrator. Efficiencies for both the normalizer and target genes were 100% ±10%. 
Primary murine leukaemic T cell isolation and ex vivo culture 
Primary TJ2‐Tg leukaemic cells were obtained as single cell suspensions from the thymus or spleen, 
after gentle dissociation and filtration through 70 μm nylon cell strainers. Bone marrow single cell 
suspensions were obtained by flushing phosphate‐buffered saline (PBS) through tibiae and femora. 
For molecular analyses, primary cells were cultured in complete RPMI medium at 2 × 106 cells/ml 
and treated with either DMSO (control), 1 μg/ml actinomycin D (ActD), 50 μg/ml cycloheximide 
(CHX), 10 ng/ml PMA and 250 ng/ml ionomycin (PMA+Iono) (all from Sigma‐Aldrich), 10 μmol/l 
Tetracyclic Pyridone 6 (InSolution Jak Inhibitor I, JAKi) or 10 μmol/l BMS‐345541 (IKKi) (both 
from Calbiochem), as indicated. 
Co‐cultures 
Ltbr+/− and Ltbr−/− mouse embryonic fibroblasts (MEFs) were prepared by standard procedures. 
MEFs and the MS5 murine bone marrow stromal cell line, provided by Dr. Françoise Pflumio (CEA, 
Fontenay‐aux‐Roses, France), were maintained in Dulbecco's modified Eagle medium (DMEM; 
Lonza) or α minimal essential medium (αMEM, Gibco, Grand Island, NY, USA), respectively, and 
supplemented with 10% FBS (PAA), 2 mmol/l L‐glutamine, antibiotics, and 0·1 mmol/l 2‐
mercaptoethanol (Gibco). TJ2‐Tg leukaemic cells (1 × 106 cells/ml) were co‐cultured in triplicate 
with confluent MS5 cells or MEFs in complete RPMI medium. Co‐cultured leukaemic cells in 
suspension (non‐adherent) were collected for flow cytometry analysis. The remaining culture was 
washed twice with PBS and then incubated with enzyme‐free cell dissociation buffer (Gibco) at 
37°C. Dissociated leukaemic cells (adherent) were discriminated from MS5 or MEFs through flow 
cytometry detection of the Thy1.2 T‐cell surface marker. 
Flow cytometry and cell sorting 
Single‐cell suspensions were stained with fluorochrome‐labelled antibodies and detected in a FACS 
Calibur flow cytometer (BD Biosciences, San Jose, CA, USA) or sorted using a FACSAria I (BD 
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Biosciences), as indicated. Fluorescein isothiocyanate (FITC)‐, R‐phycoerythrin (PE)‐, PE‐cyanin 5 
(PE‐Cy5)‐, or allophycocyanin (APC)‐conjugated antibodies specific for CD3ε (145‐2C11), CD25 
(PC61), CD69 (H1.2F3), CD4 (GK1.5), CD8 (53‐6.7), CD24 (M1/69), CD44 (IM7) and Thy1.2 (30‐
H12) (BioLegend, San Diego, CA USA) were used. Membrane‐bound LTβR ligands were detected 
using the muLTβR‐huIgG (LTβR‐Fc) fusion protein, as previously described (Ansel et al, 2000). 
Intracellular LTβ was detected in paraformaldehyde‐fixed saponin‐permeabilized cells using a 
hamster anti‐mouse LTβ (BBF6.BF12) monoclonal antibody (Browning et al, 1997). The LTβR‐Fc 
fusion protein (and human IgG negative control) and the hamster anti‐mouse LTβ (and anti‐KLH 
Armenian hamster Ig Ha4/8 negative control), all kindly provided by Dr. Jeffrey L. Browning 
(Biogen Idec and Boston University School of Medicine), were visualized using PE‐conjugated 
AffiniPure F(ab’)2 fragment donkey anti‐human IgG (H+L) (Jackson ImmunoResearch 
Laboratories) and FITC‐conjugated goat anti‐hamster (Armenian) IgG (BioLegend) secondary 
antibodies, respectively. Nonviable cells were excluded from analyses by propidium iodide (Sigma‐
Aldrich) or 7‐AAD (BioLegend) staining and appropriate gating. The data were analysed on 
CellQuest (BD Biosciences) software. 
Statistics 
Statistical analyses were performed using Prism 5 (GraphPad Software, La Jolla CA, USA). Statistical 
tests were used as indicated in figure legends. Kaplan–Meier survival curves were plotted 
and P values were calculated using the log‐rank Mantel Cox test. A P < 0·05 was considered 
statistically significant. 
 
RESULTS 
Lymphotoxin gene expression in T‐ALL patient cells 
Initial analysis of LTA and LTB transcripts and cell surface LT protein showed heterogeneous but 
detectable expression in several human T‐ALL cell lines, but not in the Nalm6 B‐cell precursor 
leukaemia cell line (Fig 1A, B). LTA and LTB mRNA and surface LT expression was upregulated by 
phorbol ester treatment and blocked by an IKK inhibitor in all T‐ALL cell lines tested (Fig 1C–E). 
Together, these data confirmed previous reports obtained with other T‐ALL cell lines 
(Sung et al, 1988; Ware et al, 1992) indicating that the LT genes and LTα1β2 heterotrimers are 
expressed in human T‐ALL cells in an NF‐κB‐dependent manner. 
Analysis of a publically available large multicentre dataset of 2022 leukaemia patient and 74 non‐
malignant bone marrow (BM) samples (Haferlach et al, 2010) showed that LTA and LTB genes 
were significantly more expressed in T‐ALL and other lymphoid malignancies than in myeloid 
malignancies or non‐malignant BM (Fig 2A). Human thymocytes express LT (Wolf & Cohen, 1992), 
so we evaluated LTA and LTB expression in T‐ALL paediatric patient samples (Table SII) as 
compared to age‐matched human thymocytes. By doing so, we found LTA and LTB expression in 
normal thymocytes and T‐ALL samples, albeit heterogeneously in the latter, some expressing levels 
that were higher, while others were lower than those found in thymocytes (Fig 2B). To determine 
whether LT gene expression was associated with particular molecular or oncogenic subgroups 
(Graux et al, 2006), we assessed LTA and LTB expression in a larger cohort of 49 primary T‐ALL 
patients by microarray analysis followed by RT‐qPCR validation in a subset of 33 patients (see 
Table SIII for the immunophenotypic and genetic characteristics of T‐ALL diagnostic samples). 
Molecular subtypes were classified by hierarchical clustering analysis (HCA) according to the 
expression of genes previously associated with each subtype (Homminga et al, 2011). 
The LTA and LTB genes were expressed at variable levels in the different molecular subtypes, but 
expression of LTA and LTB was significantly higher in the TAL/LMO molecular subgroup than in 
the remaining samples (Fig 1C). RT‐qPCR analyses corroborated that LTA and LTB were expressed 
at higher levels in the TAL/LMO T‐ALL subgroup than in immature T‐ALL (Fig 1D and Table SIII). 
Together, these data indicate that higher LT expression is associated with a particular subset of T‐
ALL patients. 
LT expression in a mouse model of cortical/mature T‐ALL 
The TAL/LMO molecular subtype of T‐ALL has been associated with αβ T‐cell receptor (TCR) 
lineage differentiation, cell surface expression of αβTCR and CD3, and cortical/mature 
immunophenotype (Ferrando et al, 2002; Asnafi et al, 2004; Soulier et al, 2005; Graux et al, 2006). 
Moreover, TAL/LMO samples were reported to cluster preferentially with post‐β‐selection human 
thymocyte subsets, including immature CD4 single‐positive (SP), CD4/CD8 double‐positive (DP), 
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and mature CD4 and CD8 SP cells (Soulier et al, 2005). To study the role of LT in T‐ALL 
development, we used TEL‐JAK2 transgenic mice (TJ2‐Tg), a model of cortical/mature T‐ALL that 
is characterized by the presence of CD4/CD8 DP and CD8 SP leukaemic cells, expression of surface 
αβTCR, CD3 and CD5, and responsiveness to TCR stimulation (Carron et al, 2000; dos 
Santos et al, 2007). Furthermore, unsupervised clustering analysis of four TJ2‐Tg leukaemic 
samples and nine thymocyte subpopulations, based on the expression levels of 163 highly variable 
genes, revealed that the latter clustered with double negative stage 4 (DN4), CD8 ISP and DP 
thymocytes (Fig S1 and Table SIV). These results indicate that TJ2‐Tg mouse leukaemias, like most 
TAL/LMO T‐ALL cases, are malignancies of late cortical, post‐β‐selection thymocytes. We first 
assessed Lta and Ltb expression in primary TJ2‐Tg leukaemic cells from diseased mice, and found 
these genes to be expressed on average at four‐ to five‐fold higher levels than wild‐type thymocytes 
(Fig 3A). Additionally, Lta and Ltb expression was higher in TJ2‐Tg leukaemic cells than in sorted 
CD4 SP thymocytes, which are one of the main sources of LTβR ligands in the adult thymus (Fig 3B) 
(Boehm et al, 2003; Hikosaka et al, 2008). These results show that, similarly to human T‐ALL 
samples, murine TEL‐JAK2 leukaemic cells present high LT expression. 
To study how LT expression is regulated in TJ2‐Tg leukaemic cells, we inhibited the JAK/STAT and 
IKK/NF‐κB signalling pathways, which were reported to be activated in these cells 
(Carron et al, 2000; dos Santos et al, 2008) and to induce Lta and Ltb expression in T lymphocytes 
(Shebzukhov & Kuprash, 2011). Treatment of leukaemic cells with a pan‐JAK inhibitor 
downregulated Lta (and the control Socs2 gene) but not Ltb mRNA expression (Fig 3C). Similarly 
to human T‐ALL cell lines, mouse leukaemic cell treatment with an IKK kinase inhibitor markedly 
downregulated both Ltaand Ltb mRNAs (and the control Nfkb2 gene) (Fig 3D). As expected, the 
IKK inhibitor blocked Ltaand Ltb induction by PMA/ionomycin in TJ2‐Tg leukaemic cells (Fig S2). 
It is worth noting that short treatment with these inhibitors did not induce significant leukaemic 
cell death (data not shown). Together, these experiments indicate that JAK and IKK kinases are key 
regulators of lymphotoxin gene expression in human and mouse T‐ALL cells. 
In thymocytes, NF‐κB transcription factors are activated by pre‐TCR and αβTCR signalling 
(Moore et al, 1995; Aifantis et al, 2001). Given that Lta and Ltb expression is induced by TCR 
during TCR‐mediated thymocyte positive selection (Irla et al, 2012), we reasoned that the pre‐TCR 
or TCR could regulate LT gene expression in leukaemic cells. Quantification of Lta and Ltb mRNAs 
in TJ2‐Tg;Rag2−/− leukaemic cells, which are pre‐TCR and TCR‐deficient (dos Santos et al, 2007), 
showed that Ltb, but not Lta expression was decreased, as compared to pre‐TCR/TCR‐proficient 
TJ2‐Tg leukaemic cells (Fig 3E). These data indicate that TCR signalling induces Ltb gene 
expression in T‐ALL cells. 
LTα1β2 heterotrimer surface expression on TEL‐JAK2 T‐ALL cells is 
downmodulated in vivo and depends on de novo protein synthesis 
To detect LT surface protein on TJ2‐Tg cells, we first treated cells with PMA and ionomycin. 
Consistent with mRNA expression results, we detected membrane‐bound LTβR ligands at higher 
levels in TJ2‐Tg leukaemic cells than in wild‐type thymocytes (Fig S3). However, in untreated 
leukaemic cells, LT protein was detected only upon cell permeabilization (Fig 4A). Interestingly, 
upon ex vivo culture, primary leukaemic cells showed LTβR‐Fc staining, peaking at around 24 h 
(Figs 4A, B and S4). Anti‐LTβ monoclonal antibody (mAb) pre‐incubation blocked completely the 
cell surface LTβR‐Fc signal in ex vivo‐cultured and in PMA/ionomycin‐treated cells, indicating that 
only LTα1β2 heterotrimers but not LIGHT were expressed at the cell surface (Figs 4A and S5A). 
Collectively, these results indicate that ex vivo‐cultured or PMA/ionomycin‐stimulated TJ2‐Tg 
leukaemic cells express surface LTα1β2 heterotrimers. 
The observed LT cell surface expression following ex vivo culture and PMA/ionomycin stimulation 
of mouse leukaemic cells could result from a combination of de novo protein synthesis and protein 
subcellular relocalization. To assess the role of de novo protein synthesis, we blocked transcription 
and translation by treating TJ2‐Tg leukaemic cells with actinomycin D or cycloheximide, 
respectively. Both compounds blocked LTα1β2 cell surface induction upon either ex vivo culture or 
PMA/ionomycin stimulation (Fig S5A, B), indicating that sustained LTα1β2surface expression in 
leukaemic cells depends on de novo mRNA and protein synthesis in both conditions. To verify 
whether ex vivo culturing also induced Lta and Ltb mRNA, we performed RT‐qPCR analysis in 
leukaemic cells freshly collected or cultured ex vivo. Ltb, but not Lta mRNA expression increased 
following ex vivo culture (Fig S5C). Together, these results indicate that LTα1β2 expression at the 
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surface of ex vivo‐cultured and stimulated leukaemic cells depends on LT gene transcription and 
continuous protein synthesis. 
Microenvironmental LTβR downmodulates cell surface LT expression on TEL‐JAK2 
leukaemic T cells 
Given that surface LT expression was detected on primary leukaemic cells only upon ex vivoculture, 
we sought to determine whether lack of LT expression in vivo depended upon interaction with 
LTβR expressed by stromal cells. To this end, we inoculated TJ2‐Tg leukaemic cells 
in Ltbr+/− and Ltbr−/− mice and collected expanded cells for analysis 3–4 weeks later. Similarly to 
spontaneously generated leukaemic cells (Fig 4), leukaemic cells collected from Ltbr‐proficient 
mouse organs (gated on CD8+CD25+ cells) did not display detectable LTα1β2 surface expression 
(Fig 5A). In contrast and strikingly, LTα1β2 surface expression was markedly sustained in 
leukaemic cells collected from different tissues (thymus, spleen, bone marrow and peripheral 
blood) of Ltbr−/− recipient mice (Figs 5A, B and S6). Similar results were obtained upon inoculation 
of TJ2‐Tg;Ltbr−/− leukaemic cells in Ltbr+/− and Ltbr−/− mice (data not shown). These results 
indicate that LTα1β2 expression on the TJ2‐Tg leukaemic cell surface is downmodulated when these 
cells are localized within LTβR‐expressing tissue microenvironments. 
To investigate whether downmodulation of LTα1β2 surface expression depends on direct cell 
contact, we co‐cultured TJ2‐Tg leukaemic cells with stromal cell lines. The bone marrow‐derived 
MS5 stromal cell line, which expresses surface LTβR (Fig S7), was shown to sustain the survival of 
co‐cultured TJ2‐Tg leukaemic cells (Fig 5C). Upon co‐culture, leukaemic cells adhering to the MS5 
monolayer showed lower levels of surface LTα1β2 than either non‐adhering co‐cultured leukaemic 
cells or leukaemic cells cultured in absence of MS5 cells (Fig 5D, E). Conditioned medium collected 
from co‐cultured leukaemic cells with MS5 cells did not impair LTα1β2upregulation in leukaemic 
cells cultured in the absence of MS5 cells (Fig S8), indicating that soluble factors produced in co‐
cultures are not sufficient for LTα1β2 downmodulation. To determine whether interaction with 
LTβR was required for LTα1β2 downmodulation, TJ2‐Tg leukaemic cells were co‐cultured with 
either Ltbr−/− or Ltbr+/− mouse embryonic fibroblasts (MEFs). Strikingly, Ltbr‐deficient, but 
not Ltbr‐proficient MEFs failed to downmodulate LT from the surface of adhering leukaemic cells 
(Fig 5F, G), thus indicating that this phenomenon is mediated by interaction with LTβR in 
microenvironmental cells. These results indicate therefore that direct contact between the 
leukaemic cell and LTβR‐expressing stromal cells is required for surface LTα1β2 downmodulation. 
Moreover, we conclude that the increased levels of leukaemic cell surface LTα1β2 in Ltbr‐deficient 
recipient mice is caused by defective LTβR expression in microenvironmental cells, and not by 
putative indirect cellular or systemic defects in Ltbr‐deficient recipient mice. 
LTβR inactivation delays leukaemogenesis in TEL‐JAK2 transgenic mice 
The above results indicate a potential LTα1β2‐LTβR functional interaction between leukaemic and 
stromal cells. To investigate whether LTβR activation is involved in T‐cell leukaemogenesis, TJ2‐Tg 
mice were bred with Ltbr knockout mice. Strikingly, we found that TJ2‐Tg;Ltbr−/− mice developed 
T‐ALL with longer latency than TJ2‐Tg;Ltbr+/− mice (median survival of 23 weeks vs. 15 weeks) 
(Fig 6A). Despite the observed delay in leukaemogenesis, Ltbr gene inactivation did not impact on 
the leukaemic cell surface marker phenotype (CD3, CD4, CD8, CD24 and CD25 expression) 
characteristic of TJ2‐Tg mice (dos Santos et al, 2007) (Fig S9), nor on endpoint tumour burden in 
lymphoid and visceral organs (Fig 6B), except for lymph nodes, which are absent in Ltbr knockout 
mice (Fütterer et al, 1998). Similar to leukaemic cells transplanted to Ltbr−/− mice, those collected 
from Ltbr‐deficient, but not from Ltbr‐proficient TJ2‐Tg mice expressed surface LTα1β2 (Fig 6C, D), 
thus confirming that LTα1β2 surface expression in both normal and malignant T cells is only 
detectable in the absence of the cognate receptor (Boehm et al, 2003). Of note, the observed delay 
in leukaemogenesis in the absence of LTβR was not linked to putative T‐cell defects, because LTβR‐
deficient mice aged 19–22 weeks, an age when most Ltbr‐proficient TJ2‐Tg mice have developed 
terminal disease, presented no major defects in cellularity and differentiation of thymocytes 
(Fig S10A–D), the targets of TJ2‐Tg‐induced transformation. Furthermore, inhibition of LT 
signalling through the administration of neutralizing LTβR‐Fc fusion protein to young pre‐
leukaemic TJ2‐Tg mice (with intact thymocyte and lymphoid organ differentiation) prolonged 
mouse survival (Fig 6E). Together, these results indicate that delayed leukaemogenesis in Ltbr‐
deficient mice could not be attributed to either T‐cell defects or absence of lymph nodes and, more 
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importantly, that LTβR signalling in non‐malignant microenvironmental cells promotes 
leukaemogenesis. 
LT signalling fosters the early stages of leukaemogenesis 
To determine the role of LTβR signalling at early stages of disease, we analysed young (8‐week‐
old) TJ2‐Tg mice without signs of disease for the presence of aberrant CD8+CD25+ cells in organs 
commonly affected by T‐ALL. CD8+CD25+ cells were consistently found, although at variable 
proportions, in the thymus of asymptomatic mice, but not to same extent in spleen, bone marrow 
and blood (Fig S11). Upon transplantation to nude mice, thymocyte suspensions including 
CD8+CD25+ cells generated secondary leukaemia (data not shown). These data confirm that the 
first malignantly transformed T cells in the TJ2‐Tg mouse model arise in the thymus. 
To investigate whether LT signalling participates in the early phases of T‐ALL, we analysed LT gene 
expression in thymocytes from 8‐week‐old asymptomatic TJ2‐Tg mice and non‐transgenic 
littermates. Interestingly, the increased proportion of CD8+CD25+ malignant thymocytes observed 
in young TJ2‐Tg mice (without thymic enlargement) was associated with 
increased Ltaand Ltb expression (Figs 6F, G and S12A, B). More specifically, significantly higher 
levels of Ltaand Ltb expression were found in samples where CD8+CD25+ cells accounted for more 
than 5% of thymocytes (Fig S12C). To investigate whether LT signalling promotes 
leukaemogenesis at the initial steps of disease, we detected malignant (CD8+CD25+) thymocytes in 
asymptomatic 8‐week‐old TJ2‐Tg mice of different Ltbr genotypes. Interestingly, the proportion of 
malignant thymocytes was significantly reduced in Ltbr‐deficient mice, as compared to Ltbr‐
proficient mice (Fig 6H). Together, these data indicate that increased LT gene expression occurs 
early in TJ2‐Tg‐induced leukaemogenesis, and that LTβR signalling at early stages accelerates 
disease progression. 
 
DISCUSSION 
Although LT expression in T‐ALL cell lines has long been known, the present study disclosed a role 
for LT expression in T‐ALL development. Indeed, by studying patient samples, cell lines and a 
transgenic mouse model, we found that T‐ALL cells express lymphotoxin protein and mRNA, that 
leukaemic cell surface LT interacts with LTβR expressed in stromal cells, and that LTβR expression 
in thymic microenvironmental cells promotes T‐ALL, especially at the early stages. LT signalling 
was shown to be involved in pro‐oncogenic interactions between leukaemic and 
microenvironmental cells in mouse models of B‐cell lymphoma and chronic lymphocytic leukaemia 
(Rehm et al, 2011; Heinig et al, 2014). Together with these findings and the observed elevated LT 
gene expression in lymphoid malignancies, our results further reinforce the notion that the LT‐
LTβR signalling axis is crucial for lymphoid cell leukaemogenesis. 
In our study, LT genes were found to be more expressed in TAL/LMO T‐ALL, a subtype associated 
with the cortical and mature stages of thymocyte differentiation (Ferrando et al, 2002; 
Asnafi et al, 2004; Soulier et al, 2005; Graux et al, 2006). Being considered a thymocyte 
malignancy, T‐ALL is associated with expression of thymocyte differentiation markers. As such, LT 
gene expression in T‐ALL may reflect either the differentiation stage of the cell of origin or the 
oncogenic process itself. Regardless of the mechanism involved, the presented data suggests that, 
at least in a subset of patients, T‐ALL cells can interact with and modulate LTβR‐expressing 
microenvironments through LT expression. 
In agreement with previous reports (Browning et al, 1997), signalling pathway activation by 
phorbol ester and ionophore treatment induced LT gene transcription and surface 
LTα1β2expression in both mouse primary T‐ALL cells and human cell lines. By treating TJ2‐Tg 
leukaemic cells and several T‐ALL cell lines with pharmacological inhibitors, we verified that both 
basal and PMA/ionomycin‐induced LT expression in mouse and human T‐ALL was dependent on 
IKK/NF‐κB activity, and that Lta expression in TJ2‐Tg leukaemic cells was dependent on JAK kinase 
activity. NF‐κB signalling in T cells can be activated by αβTCR or pre‐TCR signalling 
(Moore et al, 1995; Aifantis et al, 2001; Cheng et al, 2011). Supporting the notion that these 
receptor complexes may upregulate LT genes in T‐ALL, we observed that Ltb mRNA levels were 
reduced in TJ2‐Tg leukaemic cells lacking pre‐TCR/αβTCR (Rag2‐deficient). Thus, our findings 
indicate that Ltb gene expression in T‐ALL is induced by TCR or pre‐TCR signalling in an NF‐κB‐
dependent manner. 
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Despite the high levels of Lta and Ltb expression in TJ2‐Tg leukaemic cells, surface LTα1β2 was 
barely detectable in cells collected from LTβR‐proficient mice, but were readily detected in 
leukaemic cells collected from LTβR‐deficient mice, as previously reported for mature T cells 
(Boehm et al, 2003). These results thus suggest that upon LTβR activation on stromal cells, the 
surface levels of LTα1β2 in thymocytes are downmodulated, possibly due to an autoregulatory 
mechanism to dampen LTβR activation. Supporting this hypothesis, LTα1β2 heterotrimers were 
found to be upregulated at the leukaemic cell surface upon ex vivo culture in the absence of stromal 
cells. Surface LT downmodulation was directly linked to LTβR expression, as demonstrated by the 
detection of surface LT in leukaemic cells in direct contact with LTβR‐deficient MEFs, but not in 
leukaemic cells in contact with LTβR‐expressing MEF or MS5 stromal cells. Furthermore, surface 
LT downmodulation depended on direct contact with LTβR‐expressing cells, since it was weak in 
co‐cultured leukaemic cells that did not adhere to stromal cells and it was not induced by soluble 
factors from co‐culture conditioned medium. Therefore, these data show that surface LT 
downmodulation depends on direct interaction with LTβR. 
Our results indicate that LT signalling occurs in the initial stages of TEL‐JAK2‐induced murine T‐
ALL, which, similar to TAL/LMO cases in humans, presents features of cortical/mature T‐cell 
leukaemia. Indeed, increased LT gene expression was detected in thymocytes from young 
asymptomatic TJ2‐Tg mice. Furthermore, LTβR deficiency hampered the initial expansion of T‐ALL 
cells in the thymus. Given that LTβR is expressed in thymic stromal cells, including epithelial cells 
and fibroblasts, but not thymocytes (Seach et al, 2008), our findings indicate that emerging LT‐
expressing leukaemic cells require LTβR‐expressing thymic stromal cells for accelerated disease 
onset. LTβR‐Fc‐mediated blockade of LTβR signalling in pre‐leukaemic TJ2‐Tg mice indicated that 
early interference with this pathway delays leukaemogenesis. At the terminal phase of TJ2‐Tg‐
induced T‐ALL, we observed no significant differences in tumour burden, indicating that at later 
stages of disease progression, LTβR activation plays a less prominent role. This suggests that 
interaction of LT‐expressing leukaemic cells with LTβR‐expressing stromal cells plays a pro‐
leukaemogenic role when the emerging malignant cells are in small numbers but not after 
expansion and consequent reduced contact with the former cells. 
The identity of the LTβR‐expressing stromal cells and the mechanisms by which their activation 
promotes leukaemogenesis remain to be elucidated. Given that LTβR is known to activate the 
noncanonical NF‐κB pathway (Ganeff et al, 2011) and RelB expression in stromal cells has been 
implicated in murine T‐ALL (dos Santos et al, 2008), we postulate that LTα1β2 expression in 
emerging malignant thymocytes activates an NF‐κB‐dependent transcriptional programme in 
thymic microenvironmental cells that promotes T‐cell leukaemogenesis. Cytokines (e.g. 
BAFF/TNFSF13B) and chemokines (e.g. CCL5, CCL19, CCL21, CXCL12 and CXCL13) are possibly 
involved, because several of these are activated by LTβR in stromal cells (Dejardin et al, 2002; 
Seach et al, 2008). Interestingly, expression of CXCR5, the gene encoding the CXCL13 receptor, was 
found to correlate with LTB expression in our microarray analysis of T‐ALL patients (data not 
shown), raising the question of whether CXCL13 induces LT in this disease. As shown in Fig S1, TJ2‐
Tg leukemic cells express several chemokine receptor genes, including Ccr7 and Ccr9. CCL21, a 
CCR7 ligand, was found to be highly expressed in TJ2‐Tg lymphomas (by RT‐qPCR and 
immunohistolgical staining) but such expression was not affected by LTβR deficiency (data not 
shown). In addition, Ccr7 deficiency in TJ2‐Tg mice did not delay leukemogenesis (unpublished 
data), which indicates that the role of LTβR in leukemogenesis is not mediated by 
CCL19/CCL21/CCR7 signalling. The identity of the LTβR target proteins, chemokines or others, and 
whether LTβR‐expressing cells from other organ microenvironments are also involved in 
interaction with human or murine T‐ALL, merit further investigation in future studies. 
In summary, the identification of molecules mediating crosstalk between T‐ALL and 
microenvironmental cells is important to understand how T‐ALL arises from thymocytes and to 
determine which microenvironmental signals play a role in the progression, maintenance and 
chemoresistance of this malignancy. Several studies have highlighted the role of stromal factors in 
T‐ALL. Secreted molecules, such as IL7 and IL18, and membrane‐bound Notch ligands were shown 
to promote T‐ALL in vitro proliferation and progression in xenografted mouse spleen and bone 
marrow (Silva et al, 2011; Uzan et al, 2014; Minuzzo et al, 2015; Yin et al, 2015). Moreover, 
competitive access to growth signals from the thymic microenvironment has been shown to be 
important for T‐ALL development (Martins et al, 2014). The present work further demonstrates 
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the importance of the microenvironment in T‐ALL and indicates that LT signalling is important in 
the early (thymic) stages of this malignancy. Future studies should address whether LT signalling 
is involved in later phases of T‐ALL progression and whether it is a potential therapeutic target in 
combination with other agents. 
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Figure 1 - T‐cell acute lymphoblastic leukaemia (T‐ALL) patient cell lines express lymphotoxin 
proteins in an NF‐κB‐dependent manner. (A) RT‐qPCR quantification of LTA and LTB mRNA 
levels (relative to GAPDH expression) in the indicated cell lines (mean ± range of technical 
triplicates of one representative analysis of at least 2 performed for each cell line). (B) Cell 
surface immunostaining with LTβR‐Fc (solid line) or secondary antibody alone (grey shading) 
on the indicated T‐ALL cell lines and Nalm6 B‐cell line. (C) RT‐qPCR quantification of LTA and 
LTB (relative to GAPDH expression) in DND41, PF382, SUPT1 and Nalm6 cell lines treated for 
10 h with either IKK inhibitor (IKKi), phorbol 12‐myristate 13‐acetate (PMA) or dimethyl 
sulfoxide (DMSO) (mean ± range of technical triplicates). (D) Statistical analyses of combined 
RT‐qPCR data from three T‐ALL cell line biological replicates (DND41, PF382, and SUPT1). P 
values determined by paired t‐tests are indicated. (E) LTβR‐Fc immunostaining of indicated cell 
lines treated for 10 h with PMA, PMA plus IKKi, or DMSO. 
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Figure 2 - T‐ALL patient samples express lymphotoxin genes. (A) Microarray (GEO GSE 13159) 
analysis of LTA and LTB gene expression levels in several human samples: B‐ALL, B‐cell acute 
lymphoblastic leukaemia (n = 576); T‐ALL, T‐cell acute lymphoblastic leukaemia (n = 174); CLL, 
chronic lymphocytic leukaemia (n = 448); AML, acute myeloid leukaemia (n = 542); CML, 
chronic myeloid leukaemia (n = 76); MDS, myelodysplastic syndrome (n = 206); Non‐leukaemia, 
non‐leukaemia and healthy bone marrow samples (n = 74). Lines, bars and whiskers represent 
the median, quartiles and minimum and maximum values, respectively. P values were calculated 
by pairwise comparisons between B‐ALL and T‐ALL, and T‐ALL and AML using the two‐tailed 
unpaired Student's t test with or without Welch′s correction to account for unequal variances 
when appropriate. See Table SV for further pairwise comparisons. (B) RT‐qPCR quantification 
of LTA and LTB mRNA levels in human thymocytes (n = 7) and T‐ALL patient samples (n = 8) 
(relative to RNA18S5 rRNA expression); mean of technical triplicates for each sample. (C) LTA 
and LTB gene expression, as determined by microarray analysis, in 49 T‐ALL samples, classified 
according to molecular subtype [HOXA (n = 5), immature (n = 4), proliferative (n = 5), TLX (n = 
12) and TAL/LMO (n = 23)], and 2 human thymocyte samples (bar represents mean 
expression). P values were calculated by comparing TAL/LMO and the other molecular subtypes 
combined (i.e. HOXA, immature, proliferative and TLX) using the two‐tailed unpaired Student's 
t test. (D) RT‐qPCR quantification of LTA and LTB (relative to ABL1 expression and calibrated 
to expression in Jurkat cells) in 33 T‐ALL patient samples classified according to molecular 
subtype [HOXA (n = 3), immature (n = 4), proliferative (n = 4), TLX (n = 8) and TAL/LMO (n = 
14)]. P values were calculated by comparison between TAL/LMO and the other molecular 
subtypes combined (i.e. HOXA, immature, proliferative and TLX) using the two‐tailed unpaired 
Student's t test alone or with Welch′s correction to account for unequal variances when 
appropriate. 
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Figure 3 - Mouse T‐ALL cells express lymphotoxin genes in an NF‐κB‐dependent manner. (A) 
RT‐qPCR quantification of Lta and Ltb in leukaemic cells from independent TJ2‐Tg mouse 
thymic lymphomas (n = 11) and wild‐type thymocytes (WT; n = 4). Results are expressed as 
mean + 95% confidence interval (CI). P values determined by the two‐tailed, unpaired t test with 
Welch′s correction. (B) Two WT thymocyte and 4 TJ2‐Tg leukaemic cell samples randomly 
selected from those tested in (A) were compared with sorted CD4+CD8+ double‐positive (DP) 
and CD4+ single‐positive (CD4 SP) thymocytes (from 2 independent cell sorting experiments). 
Results are expressed as mean + 95% CI. (C,D) Lta, Ltb, Socs2 and Nfkb2 mRNA expression were 
quantified by RT‐qPCR in three independent TJ2‐Tg leukaemic cell samples treated ex vivo for 
10 h with either DMSO, JAKi or IKKi. Results are expressed as mean ± SEM. P values determined 
by two‐tailed, paired t tests (E) RT‐qPCR quantification of Lta and Ltb mRNA levels in Rag2‐
deficient TJ2‐Tg leukaemic cells (TJ2‐Tg;Rag2−/−; n = 6) and control leukaemic cells (TJ2‐Tg; n 
= 4). Results are expressed as mean + 95% CI. P values determined by two‐tailed, unpaired t 
tests with Welch′s correction. 
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Figure 4 - Mouse T‐ALL cells express LTα1β2 heterotrimers. (A) Flow cytometry immunostaining 
of LTβR ligands (black solid line) on representative TJ2‐Tg leukaemic cells freshly collected (in 
vivo) or cultured ex vivo for 22 h with LTβR‐Fc protein or anti‐LTβ mAb on viable (left and middle 
panels) or fixed/permeabilized (ic) (right panels) cells. The secondary antibody alone or non‐
specific mAb were used as negative controls for LTβR‐Fc and LTβ mAb, respectively (grey shading). 
LTβR‐Fc immunostaining was also performed following anti‐LTβ mAb pre‐incubation (black 
dashed line). (B) LTβR‐Fc staining mean fluorescence intensity (MFI) for seven independent 
leukaemic cell samples before (0 h) and after 22 h of ex vivo culture. P value determined by the 
two‐tailed, paired t‐test. 
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Figure 5 - LTα1β2 heterotrimer expression on leukaemic T cells depends on LTβR expression in 
microenvironmental cells. (A) Cell surface immunostaining with LTβR‐Fc (solid line) or secondary 
antibody alone (grey shading) of thymic CD8+CD25+ TJ2‐Tg leukaemic cells collected 3 weeks post‐
inoculation of Ltbr+/− and Ltbr−/− mice. (B) LTβR‐Fc mean fluorescence intensity (MFI) subtracted 
from control MFI of CD8+CD25+ cells collected from 3 to 4 transplanted mice of the indicated 
genotypes. One representative of three independent experiments is shown as the mean + 95% 
CI. P value determined by the two‐tailed, unpaired t test with Welch′s correction. (C) TJ2‐Tg 
leukaemic cell viability upon 3 days in culture medium alone (isolated) or in co‐culture with MS5 
cells. Representative results of three experiments are expressed as the mean ± SEM of technical 
triplicates. P value determined by the two‐tailed, unpaired t test. (D) Cell surface LTβR‐Fc 
immunostaining (solid line) of TJ2‐Tg leukaemic cells cultured for the indicated times in culture 
medium alone or in co‐culture with MS5 cells. (E) LTβR‐Fc MFI subtracted from control MFI of 
leukaemic cells adhering (Adh) or non‐adhering (Non‐adh) to co‐cultured MS5 cells, or cultured in 
isolation and collected at 72 h. Results from one experiment representative of three are expressed 
as the mean ± SEM of technical triplicates. P values determined by pairwise comparisons using 
two‐tailed, unpaired t tests. (F) Phase contrast microscopy depicting TJ2‐Tg leukaemic cells 
adhering (arrowhead) or non‐adhering (arrow) to mouse embryonic fibroblasts (MEFs), after 24 h 
of co‐culture. (G) Cell surface LTβR‐Fc immunostaining of TJ2‐Tg leukaemic cells co‐cultured for 
24 h with Ltbr+/− or Ltbr−/− MEFs. Leukaemic cells adherent or non‐adherent to MS5 or MEF cells 
were gated on Thy1.2+ cells. 
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Figure 6 - LTβR inactivation delayed TEL‐JAK2‐induced leukaemogenesis. (A) Kaplan–Meier 
survival curves for cohorts of TJ2‐Tg;Ltbr+/− and TJ2‐Tg;Ltbr−/− mice. Tick marks represent 
leukaemia‐free mice followed until the indicated age. (B) Weights of thymus, spleen, liver and 
lymph nodes (mandibular, axillary, sub‐iliac and jejunal) collected from terminally ill TJ2‐
Tg;Ltbr+/− (n = 53) and TJ2‐Tg;Ltbr−/− (n = 33) mice represented as the mean + 95% CI. (C) Flow 
cytometry immunostaining of representative thymic TJ2‐Tg;Ltbr−/− leukaemic cells using LTβR‐Fc 
(black solid line) or secondary antibody alone (grey shading). Where indicated, cells were pre‐
incubated with an anti‐LTβ mAb (black dashed line). (D) LTβR‐Fc mean fluorescence intensity 
(MFI) (median) of TJ2‐Tg (n = 11) and TJ2‐Tg;Ltbr−/− (n = 5) leukaemic cells subtracted from the 
MFI of cells stained with control antibody alone. P value determined by the Mann–Whitney test. (E) 
Kaplan–Meier survival curves (P = 0·27; log‐rank test) for TJ2‐Tg mice treated with intraperitoneal 
injections of LTβR‐Fc or mouse polyclonal IgG once a week for 5 weeks, starting at 5 weeks of age 
(arrows). At 16 weeks all control‐treated mice were dead while half of LTβR‐Fc‐treated mice were 
still alive (P = 0·06; χ2 test) (F) Percentage of CD8+CD25+ thymocytes plotted with thymic 
weights. P = 0·4047; two‐tailed Spearman test. (G) Lta and Ltb mRNA expression levels plotted 
with the percentage of CD8+CD25+thymocytes from 8‐week‐old asymptomatic TJ2‐Tg mice (n = 10) 
(mean of triplicates for each sample). Lta, P = 0·0008; Ltb, P = 0·0174; two‐tailed Spearman test. 
For (F) and (G) r2 measures goodness‐of‐fit of linear regression. (H) Percentage of malignant 
thymocytes (as identified by CD8 and CD25 positivity) represented as the mean + 95% CI in thymi 
from 8‐week‐old TJ2‐Tg mice. Pvalue determined by pairwise comparison between +/+ and −/− 
using the Mann–Whitney test. 
